Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.05. | EQL Pharma AB: Year-End Report April 2024 - March 2025 | 232 | GlobeNewswire (Europe) | Sales and operating profit growth, significant product acquisition completed, 11 new products, first deal outside Europe and graduation year passed
January - March 2025
Consolidated sales during... ► Artikel lesen | |
23.04. | Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2024/25 | 1 | Cision News | ||
EQL PHARMA Aktie jetzt für 0€ handeln | |||||
11.03. | EQL Pharma signs a distribution agreement with a large distributor in the GCC countries for Mellozzan (melatonin) | 1 | Cision News | ||
07.03. | EQL Pharma AB: New financial targets for the period 2024/25 - 2028/29 | 102 | GlobeNewswire (Europe) | EQL will shortly conclude the 5-year plan for 2020/21 - 2024/25. Thus, the Company today 7 March presents new financial targets for the period 2024/25 - 2028/29.
Our target is to increase sales at... ► Artikel lesen | |
24.02. | EQL PHARMA AB: Nomination committee for the 2025 Annual General Meeting | 1 | Cision News | ||
05.02. | EQL Pharma AB: Interim Report April - December 2024 | 129 | GlobeNewswire (Europe) | Sales and operating profit growth, significant product acquisition signed
October - December 2024
Consolidated sales during the third quarter, October to December amounted to SEK 92.2 (70.2) million... ► Artikel lesen | |
31.01. | EQL Pharma AB completes the asset purchase of a product portfolio from Medilink A/S | 2 | Cision News | ||
29.01. | EQL Pharma invites to Capital Markets Day, March 7, 2025 | 3 | Cision News | ||
17.01. | EQL Pharma AB successfully issues senior secured bonds | 3 | Cision News | ||
13.01. | Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2024/25 | 2 | Cision News | ||
13.01. | EQL Pharma AB (publ) contemplates to issue senior secured bonds and publishes preliminary figures as of 31 December 2024 | 4 | Cision News | ||
10.12.24 | Correction: EQL Pharma AB (publ) signs an asset purchase agreement in respect of the acquisition of a portfolio with original pharmaceuticals | - | Cision News | ||
10.12.24 | EQL Pharma AB (publ) signs an asset purchase agreement in respect of the acquisition of a portfolio with original pharmaceuticals | 1 | Cision News | ||
06.11.24 | EQL Pharma AB: Interim Report April - September 2024 | 80 | GlobeNewswire (Europe) | Sales and operating profit growth, new products added to the pipeline
July - September 2024
Consolidated sales during the second quarter, July to September amounted to SEK 85.2 (59.6) million, an... ► Artikel lesen | |
19.08.24 | EQL Pharma AB: Bulletin from the annual general meeting in EQL Pharma AB on 19 August 2024 | 128 | GlobeNewswire (Europe) | Today, on 19 August 2024, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and allocation of the company's... ► Artikel lesen | |
08.08.24 | EQL Pharma AB: Interim Report April - June 2024 | 123 | GlobeNewswire (Europe) | Sales and operating profit growth, new products added to the pipeline
April - June
Consolidated sales during the first quarter, April to June amounted to SEK 82.8 (56.2) million, an increase of 47%.... ► Artikel lesen | |
04.07.24 | Nasdaq Stockholm welcomes EQL Pharma to the Main Market | 276 | GlobeNewswire | Stockholm, Jul 4, 2024 - Nasdaq (Nasdaq: NDAQ) announces that trading in the
shares of EQL Pharma AB (ticker name: EQL) will commence today on the Nasdaq
Stockholm Main Market. EQL Pharma is a Small... ► Artikel lesen | |
02.07.24 | Nasdaq Stockholm AB: Listing of EQL Pharma AB on Nasdaq Stockholm | 246 | GlobeNewswire | On request of EQL Pharma AB, company registration number 556713-3425, Nasdaq
Stockholm has admitted the company's shares to trading with effect from July 4,
2024.
As per today's date the company has... ► Artikel lesen | |
27.06.24 | Nasdaq Stockholm AB: Listing of EQL Pharma AB on Nasdaq Stockholm | 242 | GlobeNewswire | Nasdaq Stockholm AB has assessed that EQL Pharma AB, company registration
number 556713-3425, fulfills Nasdaq Stockholm's listing requirements. Provided
that EQL Pharma AB applies for admission to trading... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
VERTEX PHARMACEUTICALS | 395,50 | +0,08 % | Vertex Pharmaceuticals Incorporated: Vertex Presents New Data on Benefits of ALYFTREK and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference | - Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with... ► Artikel lesen | |
UNITED THERAPEUTICS | 284,30 | -0,49 % | Leerink Partners maintains positive outlook on United Therapeutics stock | ||
CATALYST PHARMACEUTICALS | 22,750 | +0,22 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer | CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP... ► Artikel lesen | |
INDIVIOR | 12,200 | +0,83 % | Indivior PLC: Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained | SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing... ► Artikel lesen | |
CAMURUS | 58,30 | -0,60 % | AKTIONÄR-Tipp Camurus: Paukenschlag - Top-Deal mit Eli Lilly | Die schwedische Biotech-Gesellschaft Camurus hat am Dienstagabend eine neue Kooperations- und Lizenzvereinbarung bekanntgegeben. Kein geringerer als der US-Pharma-Konzern Eli Lilly setzt auf die innovative... ► Artikel lesen | |
BAYER | 26,435 | +0,02 % | Turbo von der FDA!: Bayer vor Comeback? Drei Wirkstoffe, die jetzt alles verändern könnten | © Foto: Oliver Berg - dpaGleich dreifacher Rückenwind für Bayer: Die FDA hat Nubeqa abgesegnet und gleich zwei neue Hoffnungsträger bringen Schwung in die Pharmasparte. Die Aktie nimmt wieder Fahrt... ► Artikel lesen | |
MERCK KGAA | 115,20 | -0,17 % | JPMORGAN stuft MERCK KGAA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA mit einem Kursziel von 155 Euro auf "Overweight" belassen. Die auf der Asco-Krebsforschertagung präsentierten Studiendaten... ► Artikel lesen | |
GSK | 18,050 | -0,03 % | BERENBERG stuft GSK auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat GSK nach gutem Lauf bei unverändertem Kursziel von 1600 Pence von "Buy" auf "Hold" abgestuft. Die Kursentwicklung des Pharmakonzerns sei in... ► Artikel lesen | |
NOVO NORDISK | 65,55 | +2,49 % | DEUTSCHE BANK RESEARCH stuft NOVO NORDISK auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Novo Nordisk mit einem Kursziel von 750 dänischen Kronen auf "Buy" belassen. Dies schrieb Emmanuel Papadakis in einem am... ► Artikel lesen | |
PFIZER | 20,510 | +0,15 % | Investor Woche: Nintendo launcht Switch 2, Tesla nach Musk-Trump-Drama im Sinkflug, EZB senkt Zinsen, Konjunkturdaten durchwachsen, Pfizer baut Stellen ab | Donald Trump und Elon Musk dominieren die Schlagzeilen: diese Woche durch das dramatisch vorgetragene Ende ihrer Männerfreundschaft. Dass Friedrich Merz im Oval Office war und die EZB die Zinsen senkte... ► Artikel lesen | |
METSERA | 27,490 | -4,12 % | Metsera, Inc.: Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association | ||
SANOFI | 89,11 | +0,01 % | Milliarden-Übernahme: Sanofi kauft sich mit 9,1 Milliarden US-Dollar in US-Biotech-Markt ein! | © Foto: Martin Joppen / SanofiDer französische Pharmariese Sanofi kündigt milliardenschweren Übernahme von Blueprint Medicines an. Die Ankündigung lässt die Aktie in die Höhe steigen!Der französische... ► Artikel lesen | |
EDWARDS LIFESCIENCES | 67,46 | -0,82 % | Is Edwards Lifesciences Stock Underperforming the Dow? | ||
ROCKET LAB | 25,440 | +0,28 % | Why Rocket Lab Corp. (RKLB) Soared On Friday | ||
EYENOVIA | 4,880 | +55,41 % | EYENOVIA, INC. - 8-K, Current Report |